Dmitri V Rozanov Selected Research

Matrix Metalloproteinase 14 (MT1-MMP)

9/2010	Internal cleavages of the autoinhibitory prodomain are required for membrane type 1 matrix metalloproteinase activation, although furin cleavage alone generates inactive proteinase.
3/2010	Timp-2 binding with cellular MT1-MMP stimulates invasion-promoting MEK/ERK signaling in cancer cells.
4/2009	Biochemical evidence of the interactions of membrane type-1 matrix metalloproteinase (MT1-MMP) with adenine nucleotide translocator (ANT): potential implications linking proteolysis with energy metabolism in cancer cells.
6/2008	Molecular signature of MT1-MMP: transactivation of the downstream universal gene network in cancer.
1/2008	Tissue inhibitor of metalloproteinases-2 binding to membrane-type 1 matrix metalloproteinase induces MAPK activation and cell growth by a non-proteolytic mechanism.
11/2006	Membrane type-1 matrix metalloproteinase confers aneuploidy and tumorigenicity on mammary epithelial cells.
9/2006	Mechanistic insights into targeting T cell membrane proteinase to promote islet beta-cell rejuvenation in type 1 diabetes.
6/2006	O-glycosylation regulates autolysis of cellular membrane type-1 matrix metalloproteinase (MT1-MMP).
6/2006	Interference with the complement system by tumor cell membrane type-1 matrix metalloproteinase plays a significant role in promoting metastasis in mice.
7/2005	Membrane type-1 matrix metalloproteinase (MT1-MMP) exhibits an important intracellular cleavage function and causes chromosome instability.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Dmitri V Rozanov Research Topics

Disease

23	Neoplasms (Cancer) 01/2018 - 03/2002
8	Breast Neoplasms (Breast Cancer) 01/2018 - 03/2002
3	Fibrosarcoma 03/2010 - 01/2005
3	Neoplasm Metastasis (Metastasis) 06/2008 - 06/2006
3	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 11/2007 - 07/2005
2	Carcinogenesis 03/2010 - 06/2008
2	Aneuploidy (Aneuploid) 11/2006 - 07/2005
2	Anthrax 07/2005 - 01/2005
2	Carcinoma (Carcinomatosis) 01/2005 - 08/2004
1	Leukemia 01/2018
1	Pathologic Processes 01/2008
1	Autolysis 06/2006
1	Melanoma (Melanoma, Malignant) 06/2006
1	Noninfiltrating Intraductal Carcinoma (DCIS) 03/2006
1	Edema (Dropsy) 02/2006
1	West Nile Fever 01/2006
1	Inhalation anthrax 07/2005
1	Chromosomal Instability (Chromosome Stability) 07/2005
1	Glioma (Gliomas) 01/2005
1	Infections 01/2005
1	Emphysema 12/2004

Drug/Important Bio-Agent (IBA)

17	Matrix Metalloproteinase 14 (MT1-MMP)IBA 09/2010 - 03/2002
15	Matrix Metalloproteinases (MMPs)IBA 06/2011 - 03/2002
9	Peptide Hydrolases (Proteases)FDA Link 04/2009 - 03/2003
5	Proteins (Proteins, Gene)FDA Link 01/2018 - 01/2005
4	AntigensIBA 01/2018 - 01/2005
4	FurinIBA 01/2005 - 03/2002
3	LigandsIBA 01/2018 - 11/2004
3	EnzymesIBA 11/2006 - 06/2006
2	Peptides (Polypeptides)IBA 01/2018 - 01/2006
2	Pharmaceutical PreparationsIBA 06/2011 - 06/2006
2	Insulin (Novolin)FDA Link 11/2007 - 09/2006
2	prinomastat (Ag3340)IBA 09/2006 - 07/2005
2	Complement System Proteins (Complement)IBA 06/2006 - 11/2004
2	anthrax toxin (anthrax lethal factor)IBA 02/2006 - 01/2005
2	Metalloproteases (Metalloproteinases)IBA 07/2005 - 12/2004
2	Integrin alphaVIBA 03/2002 - 03/2002
2	IntegrinsIBA 03/2002 - 03/2002
1	EpitopesIBA 01/2018
1	VaccinesIBA 01/2018
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2016
1	EmulsionsIBA 01/2016
1	Tissue Inhibitor of Metalloproteinase-2IBA 03/2010
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 03/2010
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 06/2009
1	Adenine NucleotidesIBA 04/2009
1	Cell Surface ReceptorsIBA 09/2006
1	N-Acetylneuraminic Acid (Sialic Acid)IBA 06/2006
1	anticomplementIBA 06/2006
1	Estrogen Receptor alphaIBA 03/2006
1	Estrogen Receptor betaIBA 03/2006
1	Arginine (L-Arginine)FDA Link 01/2006
1	pericentrinIBA 07/2005
1	ExotoxinsIBA 01/2005
1	Protease Inhibitors (Protease Inhibitor)IBA 12/2004
1	Estrogens (Estrogen)FDA Link 12/2004
1	SerpinsIBA 12/2004
1	Opsonin Proteins (Opsonins)IBA 11/2004
1	LipidsIBA 02/2004
1	Proprotein Convertases (Pro-Opiomelanocortin Converting Enzyme)IBA 03/2003
1	proteinase InIBA 03/2003
1	VitronectinIBA 03/2002
1	Tyrosine (L-Tyrosine)FDA Link 03/2002
1	Focal Adhesion Protein-Tyrosine KinasesIBA 03/2002
1	Integrin beta3 (GPIIIa)IBA 03/2002
1	adhesion receptorIBA 03/2002
1	Integrin alpha ChainsIBA 03/2002

Therapy/Procedure

4	Therapeutics 06/2009 - 03/2003
1	Immunotherapy 01/2016
1	Injections 11/2007
1	Rejuvenation 09/2006
1	Emergency Treatment 07/2005